Product context
Modality, stage, indication, development status, and the decision or trigger driving the assessment.
The Ex-US Regulatory Expansion Readiness Sprint is a bounded decision engagement for emerging drug companies comparing markets, preparing partner discussions, or determining whether a US package is reusable internationally.
The sprint organizes the regulatory question around the product, target-market assumptions, available evidence, dossier, local requirements, responsibilities, and execution dependencies.
The scope is designed to minimize disruption while making assumptions explicit. Confidential material is requested only after permitted systems, access, retention, and AI-use rules are agreed.
Modality, stage, indication, development status, and the decision or trigger driving the assessment.
US regulatory status, material authority decisions, prior questions, and other facts relevant to the target-market assumptions.
Available modules or sections at the agreed level, along with known gaps, owners, and current versions.
Named contributors and approvers who can validate assumptions, resolve open questions, and own final regulatory and commercial decisions.
The sprint ends with a workplan rather than an automatic retainer. Your team can execute internally, engage Durability Labs for defined work packages, or use qualified local providers where the plan requires them.
Use the gap register, responsibility map, and workplan to sequence work through the existing team.
Convert prioritized dossier, localization, submission, labeling, or lifecycle work into separately scoped managed outcomes.
Identify and coordinate qualified in-country providers for representation, filing, visits, or other local activities when needed.
Bring the asset, current US status, markets under consideration, and the trigger. We will confirm whether a readiness sprint is the right first engagement and define its scope before any confidential material is shared.